All In Biotech

Drug Trial Radar · NCT07717918

A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants

A Phase 1B Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jul 6, 2026

Primary completion

Aug 5, 2026

Study completion Aug 5, 2026

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects

Conditions

  • Healthy

Interventions

  • BL1332 eye dropsDrug

    Taken 1 time

  • BL1332 Placebo eye dropsDrug

    Taken 1 time

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular pain severity assessed by numeric pain rating scale (NPRS)Time frame: Assessed 5 seconds post-capsaicin dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 101

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.